Software
γδ TCR Repertoires Analysis
Creative Biolabs concentrates on promoting the understanding of gamma delta (γδ) T cell receptors breakthroughs in disease therapy. We will combine γδ T cell receptor (TCR) repertoires analysis research with other incredible projects around the world to boost novel γδ T cell development in unprecedented ways. In our company, our scientists specialized in γδ T cell studies will work with you to develop the most appropriate strategy that will offer the reproducible data for your research.
TCR Generation
As an expert in γδ T cell therapy development, Creative Biolabs has established an advanced technology platform aiming to provide comprehensive custom TCR generation services, including both αβ-TCR and γδ-TCR, for engineered γδT cell or γδ T cell immunotherapy development. Clients just offer us the specific antigen information or basic gene information of interest TCR, our one-stop TCR generation services can start from the design and synthesis of the target TCR gene.
γδ T cells cytotoxicity test
Creative Biolabs is a leader in the research of γδ T cells and cancer immunotherapy, we provide comprehensive γδ T cell cytotoxicity test services, including LDH cytotoxicity test, flow cytometry-based cytotoxicity test, chromium-51 release assay, impedance-based label-free real-time cytotoxicity assay…
Stem cell basic research
Creative Biolabs has been committed to bringing together highly skilled experts with varied backgrounds applicable to stem cell therapy research and development. Each of our experts plays a key role in advancing our clients' manufacturing processes and delivering exceptional results. We have extensive expertise in all aspects of cell therapy research and our extensive range of assays and services support cell therapy development. We offer both routine and custom designed assays that are regulatory compliant to ensure the safety, purity, and efficacy of your drug product. In addition, we are committed to providing high quality, GMP-compliant testing at all steps of your drug development program.
Assay development services
Empowered by leading technology and years of experience in biomedical science, Creative Biolabs offers assay development service that includes in vitro and in vivo. As a service provider, our goal is to provide the highest level of service, confidentiality and customer support.
B cell immortalization
Based on the leading-edge platform and profound knowledge in cell immortalization, the specialized and dedicated team at Creative Biolabs provides world-class solutions for B cell immortalization and helps you obtain the desired results. Our state-of-the-art technologies and highly qualified personnel guarantee that we can deliver maximum quality and flexibility in all phases of the service lifecycle.
iPSC-derived Cell Therapy Development
In the stem cells therapy, the induced pluripotent stem cells (iPSCs) which are directly derived from patients' somatic cells reprogramming to an embryonic-like state. Since iPSCs could be coaxed into the desired cell types that would already be genetically matched with the patient, the immune rejection and the ethical issues can be potentially circumvented.
Understanding the Role of Glycans in Biological Research
Glycans, also known as carbohydrates or polysaccharides, are fundamental constituents of all cellular life. They play essential roles in various biological processes, including cell-to-cell communication, immune response, and disease progression, among others. Accurate glycan purification, glycan identification, and anti-glycan antibody assays are crucial in advancing our understanding of glycans and their roles in biology and medicine. Glycan purification is a critical initial step in the study of glycans. It is the process of extracting and isolating glycans from an organism or cell culture to make them available for further study. Purification allows researchers to separate glycans for individual analysis and remove unwanted materials that may interfere with the results, thus increasing the accuracy of any subsequent procedures. Various methodologies are utilized in glycan purification, dependent on the type, structure, and purpose of analysis, ranging from chromatographic separation techniques to enzymatic methods. Once glycans are purified, the next essential step is glycan identification. Glycans are notorious for their structural complexity and heterogeneity. Hence, they pose unique challenges in terms of their identification and characterization. Glycan identification involves determining the precise chemical structure of a carbohydrate based on different pieces of evidence, such as molecular weight or size and chemical properties. Techniques used in glycan identification often include Mass Spectrometry or Nuclear Magnetic Resonance (NMR), which allow researchers to map out the exact composition of a glycan and establish an identification profile that aids future studies. After purifying and identifying glycans, scientists often utilize anti-glycan antibody assays to further their understanding of biological systems. Anti-glycan antibody assays aim to detect antibodies produced against specific glycans. These antibodies are typically a part of the immune response against pathogens, disease progression, or vaccination. Detecting these antibodies can provide valuable insights into the immune response and help researchers understand and intervene in disease states. For instance, in the case of cancer, abnormal glycan structures are often present on tumor cells. Identifying these glycans and the antibodies that recognize them helps scientists develop targeted therapies and diagnostics. Similarly, anti-glycan antibodies play a pivotal role in investigating and combating infectious diseases, where pathogens often use glycans to invade host cells. Anti-glycan antibody assays use various technologies to detect these antibodies, including enzyme-linked immunosorbent assays (ELISA), Western blotting, and microarray technologies. These assays all rely on the specific binding of an antibody to its corresponding glycan to produce a detectable signal, signifying the presence of the antibody. In conclusion, glycan purification, glycan identification, and the anti-glycan antibody assay play a significant role in elucidating the functionalities of glycans in life and health sciences. These processes underpin the essential research into diseases, their treatments, and further advancements in the field of glycobiology. Continued investment in improving these methodologies will grant broader insight into the incredible potential glycans hold for medicine and biology, equipping scientists with the necessary tools to further unravel the complex puzzle of glycans.
Research Advancement in Combating Monkeypox Virus
Research Advancement in Combating Monkeypox Virus The battle against emerging infectious diseases remains a critical frontier in the pursuit of global health security. Monkeypox, a rare but potentially severe viral infection, has recently come under the spotlight due to a surge in reported cases. Breakthroughs in monkeypox vaccine discovery, the development of mRNA vaccines, and innovative testing kits mark significant strides toward effective control and prevention. Monkeypox Vaccine Discovery The development of a robust and effective vaccine is key in combating monkeypox. Researchers worldwide are intensifying their efforts to create a monkeypox vaccine that can confer immunity against this zoonotic virus. Traditional vaccine approaches, such as live attenuated and inactivated vaccines, have shown promise in preclinical studies. These vaccines use weakened or inactivated virus forms to stimulate the immune system without causing illness. However, the frontier of monkeypox vaccine discovery has expanded with the advent of cutting-edge technologies. Novel vaccine platforms, including viral vectors and protein subunit vaccines, are being explored. These approaches aim to elicit a targeted immune response while minimizing the risk of adverse effects. Ongoing research holds the promise of not only preventing monkeypox but also establishing a foundation for tackling other emerging infectious diseases. Monkeypox mRNA Vaccine One breakthrough in the scientific community is the development of an mRNA vaccine against monkeypox. mRNA vaccines, pioneered in the fight against COVID-19, represent a revolutionary approach to vaccination. These vaccines provide the genetic instructions for cells to produce viral proteins, training the immune system to recognize and mount a defense against the virus. In the context of monkeypox, the mRNA vaccine holds immense potential. Preliminary studies have demonstrated the feasibility of this approach, with encouraging results in animal models. The advantages of mRNA vaccines, including rapid development and adaptability to emerging variants, position them as a game-changer in the quest for an effective monkeypox vaccine. As clinical trials progress, the mRNA vaccine could emerge as a beacon of hope in preventing the spread of this viral menace. Monkeypox Testing Kit Beyond vaccination, early and accurate diagnosis is paramount for controlling the spread of monkeypox. The development of rapid and reliable testing kits has become a critical component of the overall strategy. Traditional diagnostic methods, such as polymerase chain reaction (PCR) assays, have been the gold standard, but the need for simpler and quicker solutions has driven innovation in this field. Recent advancements in monkeypox testing kits have introduced user-friendly and point-of-care solutions. These kits use lateral flow assays and nucleic acid amplification to detect monkeypox with high sensitivity and specificity. The accessibility of these testing kits makes it easier to identify cases quickly, allowing for timely intervention and containment measures. Conclusion In the fight against the monkeypox virus, advancements in vaccine discovery, mRNA vaccine development, and testing kit innovation offer hope. These breakthroughs not only provide solutions for monkeypox but also contribute to the global fight against emerging infectious diseases. The synergy between these developments marks a crucial moment in the ongoing battle for public health, highlighting the resilience and ingenuity of the scientific community against viral threats.
Effective Solutions for Advancing NASH Drug Development
Nonalcoholic steatohepatitis (NASH) is a growing global health concern characterized by liver inflammation and damage caused by the accumulation of fat. The development of effective drugs depends heavily on robust experimental models. This article explores the pivotal role of NASH in vitro models and NASH mouse models in advancing drug development strategies. NASH in vitro models are indispensable tools for researchers investigating the molecular complexities of the disease. These models involve cultivating liver cells in a controlled laboratory environment, allowing scientists to observe cellular responses to various stimuli. A key advantage of NASH in vitro models is their ability to simulate the microenvironment of liver cells, providing insight into the mechanisms behind disease progression. Researchers can manipulate these models to mimic conditions like insulin resistance and oxidative stress, key factors in NASH development. Recently, significant progress has been made in refining NASH in vitro models to better mirror the complexity of the disease. Three-dimensional (3D) cell cultures, for instance, offer a more physiologically relevant environment compared to traditional two-dimensional cultures. This advancement allows for a more accurate representation of cell-cell interactions and the development of fibrosis, a hallmark of advanced NASH. While NASH in vitro models contribute greatly to our understanding of the disease, transitioning from cell cultures to living organisms is a crucial step in drug development. NASH mouse models play a pivotal role in bridging this gap, providing an overall view of disease progression in a living organism. Mouse models, often genetically modified to exhibit metabolic characteristics associated with NASH, allow researchers to assess the efficacy and safety of potential drug candidates. One challenge in NASH drug development is the multifaceted nature of the disease, involving complex interactions between different cellular and molecular pathways. NASH mouse models provide a platform for testing therapeutic interventions within a systemic context, accounting for the dynamic interactions between organs and tissues. This holistic approach is essential in evaluating the overall impact of potential drugs on metabolic parameters, inflammation, and fibrosis, providing a more comprehensive understanding of their therapeutic potential. The synergy between in vitro models of nonalcoholic steatohepatitis (NASH) and mouse models is demonstrated in the drug development pipeline. In vitro models are used for initial screenings and mechanistic studies, allowing researchers to identify promising drug candidates and understand how they work. Subsequently, these candidates are rigorously tested in NASH mouse models to evaluate their effectiveness and safety in a more complex biological system. In conclusion, in vitro studies provide intricate details that guide the selection of potential drugs, while mouse models offer a realistic and systemic platform for preclinical testing. The combination of these models not only speeds up the drug development process but also increases the likelihood of successfully translating findings from the laboratory to clinical applications. As the field continues to progress, the integration of these complementary approaches holds the key to developing effective therapeutic strategies for NASH.